Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study
Abstract Background Although the severity of coronavirus disease 2019 (COVID-19) tends to be lower in children, it can still lead to severe illness, particularly among those with chronic medical conditions. While remdesivir (RDV) is one of the few approved antiviral treatments for COVID-19 in childr...
Main Authors: | Abigail Schulz, Natalie Huynh, Margaret Heger, Mustafa Bakir |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-02-01
|
Series: | Molecular and Cellular Pediatrics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40348-024-00175-9 |
Similar Items
-
Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review
by: Pradeep Balasubramanian, et al.
Published: (2022-01-01) -
Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study
by: Valerie Xue Fen Seah, et al.
Published: (2023-12-01) -
Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center
by: Amirhosein Ghahremanian, et al.
Published: (2023-09-01) -
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01) -
Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Concetta Rafaniello, et al.
Published: (2021-06-01)